These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: What they say about protease inhibitors.
    Journal: Posit Aware; 1999; 10(1):38-43. PubMed ID: 11366522.
    Abstract:
    Dosages, costs, side effects, and drug interactions are discussed for each approved protease inhibitor: Invirase (Saquinavir, hard-gel capsules), Crixivan (Indinavir), Norvir (Ritonavir), Viracept (Nelfinavir), and Fortovase (Saquinavir, soft-gel capsules). Information on Agenerase (amprenavir), an experimental drug not yet approved by the FDA for commercial use, is also given. Protease inhibitors may require strict dosing schedules and food restrictions; most are associated with lipodystrophy (thinning of the arms, legs and face with fat accumulation in the breasts, stomach, and sometimes the upper back). The drug's manufacturer, a doctor, and an activist offer comments. Contact information is provided.
    [Abstract] [Full Text] [Related] [New Search]